Sana Biotechnology announced progress in its cell therapy programs, including a strategic collaboration with Mayo Clinic to develop SC451 for type 1 diabetes, aiming for a Phase 1 trial later this year. Positive 14-month clinical results were reported for UP421, showing survival and function of transplanted islet cells without immunosuppression. The company is also advancing SG293 for non-Hodgkin lymphoma and plans to start clinical trials soon, with SG227 for multiple myeloma expected by mid-2027. Financially, Sana ended Q1 2026 with $101.1 million in cash and a pro forma $128.9 million, supporting operations into 2027.
Sana Biotechnology sold about 21.6 million shares through its at-the-market (ATM) facility, raising approximately $69 million in net proceeds. This capital raise, combined with a separate $25 million investment from Mayo Clinic, totals around $94 mil...
Sana Biotechnology presented preclinical data for SG293, an in vivo CAR T cell therapy that targets CD8+ T cells to generate CD19-directed CAR T cells, showing potent and dose-dependent CAR T cell generation and deep B cell depletion in non-human pri...
